{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:51:51Z","timestamp":1762300311378,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00277-023-05127-3","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:50:58Z","timestamp":1679863858000},"page":"1275-1277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"102","author":[{"given":"Jie","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-jia","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-0436","authenticated-orcid":false,"given":"Hong-Hu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"issue":"13","key":"5127_CR1","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1182\/blood-2016-11-749507","volume":"129","author":"MB G","year":"2017","unstructured":"G MB, H M, T M, Devlin SM, Douer D, Park JH (2017) Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood 129(13):1878\u20131881","journal-title":"Blood"},{"issue":"5","key":"5127_CR2","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00277-021-04699-2","volume":"101","author":"Y Zhang","year":"2022","unstructured":"Zhang Y et al (2022) The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Ann Hematol 101(5):1141\u20131144","journal-title":"Ann Hematol"},{"issue":"14","key":"5127_CR3","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N Gokbuget","year":"2018","unstructured":"Gokbuget N et al (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131(14):1522\u20131531","journal-title":"Blood"},{"issue":"11","key":"5127_CR4","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","volume":"129","author":"V Frismantas","year":"2017","unstructured":"Frismantas V et al (2017) Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129(11):e26\u2013e37","journal-title":"Blood"},{"issue":"19","key":"5127_CR5","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/blood.2020008544","volume":"137","author":"H Kirchhoff","year":"2021","unstructured":"Kirchhoff H et al (2021) Venetoclax and dexamethasone synergize with inotuzumab ozogamicin\u2013induced DNA damage signaling in B-lineage ALL. Blood 137(19):2657\u20132661","journal-title":"Blood"},{"issue":"6","key":"5127_CR6","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/s41375-018-0315-6","volume":"33","author":"M Scherr","year":"2019","unstructured":"Scherr M et al (2019) Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. Leukemia 33(6):1313\u20131323","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"5127_CR7","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1182\/blood-2021-153826","volume":"138","author":"S Venugopal","year":"2021","unstructured":"Venugopal S et al (2021) A phase II study of mini-hyper-CVD plus venetoclax in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood 138(Supplement 1):1239\u20131239","journal-title":"Blood"},{"issue":"9","key":"5127_CR8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847","journal-title":"N Engl J Med"},{"key":"5127_CR9","doi-asserted-by":"crossref","unstructured":"Advani AS et al (2022) SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome\u2013negative B-cell acute lymphoblastic leukemia. J Clin Oncol 40(14):1574\u20131582","DOI":"10.1200\/JCO.21.01766"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05127-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05127-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05127-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T06:03:40Z","timestamp":1681365820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05127-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["5127"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05127-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"assertion":[{"value":"27 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval from the Institutional Review Board of the First Affiliated Hospital, College of Medicine, Zhejiang University, was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed parental consent was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}